Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Basic) (2018 - 2025)

BioNexus Gene Lab's EPS (Basic) history spans 8 years, with the latest figure at -$0.56 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.56 for Q4 2025, down 185.47% from a year ago — trailing twelve months through Dec 2025 was -$1.64 (down 517.96% YoY), and the annual figure for FY2025 was -$1.61, down 79.15%.
  • EPS (Basic) for Q4 2025 was -$0.56 at BioNexus Gene Lab, down from -$0.39 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.02 in Q4 2023 to a low of -$0.56 in Q4 2025.
  • The 5-year median for EPS (Basic) is -$0.01 (2022), against an average of -$0.1.
  • The sharpest move saw EPS (Basic) surged 308.44% in 2023, then tumbled 5807.26% in 2025.
  • Year by year, EPS (Basic) stood at $0.0 in 2021, then crashed by 1668.22% to -$0.01 in 2022, then surged by 308.44% to $0.02 in 2023, then crashed by 982.85% to -$0.2 in 2024, then plummeted by 185.47% to -$0.56 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.56, -$0.39, and -$0.34 for Q4 2025, Q3 2025, and Q2 2025 respectively.